|
.................................... Search the net .................................... |
Paediatric Pulmonology and Allergology
2004 April, Vol. VII, No. 1 (pp.2447-2452)
Antiproteinuric effect of montelukast in children with glomerulonephritis
Vytautas Baciulis, Rimante Cerkauskiene
The aim of this prospective study was to determine whether the leukotriene antagonist, Montelukast sodium, can abolish the proteinuria in children suffering from glomerulonephritis (GN). Ten children (4 females, 6 males), aged from 6 till 16 years, were included. Five children had IgA nephropathy, 4 – mesangioproliferative GN, 1 – FSGS determined by kidney biopsy. The base line proteinuria was measured in 24 hours urine collections prior the treatment, then the patients received 0.12±0.03 mg/kg/day (5-10 mg/day) of Montelukast for 4 weeks followed by 2 weeks wash out period without Montelukast. The reduction of mean proteinuria was estimated during the last week of the treatment with Montelukast. The mean proteinuria before treatment was 1.3±0.76 g/24 h and it significantly decreased to 0.67±0.5 g/24 h (p<0.041) at the end of the treatment period. The mean reduction of proteinuria was 52.5±25.0 proc. in 9/10 children and proteinuria has increased by 22.9 proc. in one case. At the end of wash out period the mean reduction of proteinuria was only 23,8±28,5 proc. and mean proteinuria was 0,95±0,54 g/24 h (p=0.25) There were no significant changes in glomerular filtration rate and mean blood pressure during the premontelukast, Montelukast treatment and postmontelukast periods. In conclusion our study shows that Montelukast may reduce proteinuria in children with glomerulonephritis. Further studies are needed to validate the efficacy of Montelukast for the treatment of children with glomerulonephritis.